BioSpace News Archive

Fact.MR, Rockville MD: Award winning market research company Fact.MR’s lab automation market opines a steady growth through 2021 and beyond, driven by key workstation equipment demand and rise in R&D activities.

The hospitals have extensive activity region and size of activity when contrasted with walking focuses and crisis care focuses.

Samsung Bioepis Co., Ltd. today announced its expansion of its global footprint to Australia with the launch of HADLIMA™ i (adalimumab), a biosimilar referencing HUMIRA ii(adalimumab) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult and paediatric Crohn’s disease, ulcerative colitis, hidradenitis suppurativa and plaque psoriasis.

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company’s Abbreviated New Drug Application (“ANDA”) for Dextrose injection 50% in the 50 mL Luer-Jet® Prefilled Syringe System.

Hyalo Technologies, a biopharmaceutical company dedicated to developing and commercializing innovative drug delivery systems and technologies, today announced a new patented technology, called Sterilization with the Hyalo Matrix

AntiCancer Inc. announces that its patent application on oral methioninase has been allowed by the United States Patent and Trademark Office.

Mallinckrodt’s Specialty Generics division honored with Collaborative Innovation Leadership Award for its COVID-19 pandemic response

Company will award grants totaling up to $150,000 to nonprofit community-based organizations that support sickle cell disease and beta-thalassemia patients and families

– Transaction to advance Tempest’s targeted oncology pipeline – - Concurrent $30M PIPE financing expected to close with merger - - Companies to host conference call today at 8:30 a.m. ET -

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma If approved , Opdivo would be the first adjuvant immunotherapy option for patients with muscle-invasive urothelial carcinoma in Europe